yamopharma

Developing L1-79 novel therapeutic, investigational new drug
Targeting the core symptoms of Autism Spectrum Disorder

[yamopharma @yamopharma]

🚨 MAJOR UPDATE for the autism community: After two strong rounds of trials, Yamo is advancing L1-79 into Phase 3 trials in early 2027, targeting core social communication challenges.

Watch this powerful 6-minute film with Dr. Tom Megerian, trial participants, and families.

New Yamo website live with full details + sign-up form 👇 https://t.co/QRtHqpC08J

What social breakthroughs matter most to you? #L179 #AutismTreatments

[yamopharma @yamopharma]

Autism still has no approved medication for core social symptoms.

Dr. Tom Megerian: L1-79 is a new treatment candidate aimed at social connection, not a cure. Phase 3 is next.

https://t.co/W641qXJSwK | https://t.co/7OtqzprvQP

#Autism #ASD #AutismTreatment #AutismResearch

[yamopharma @yamopharma]

Stories like this from autism families are why people keep asking about L1-79.

The early work focused on social communication, and those reports are part of why Phase 3 planning matters now.

L1-79 remains an experimental treatment.

Learn more at https://t.co/QRtHqpC08J

#autism #autismawareness #autismtreatment #asd #l179

[yamopharma @yamopharma]

Can my child join the L1-79 trial right now?

We have been hearing this question a lot lately.

Phase 3 of FDA trials are not currently open for enrollment, but we keep all your inquiries on file when you sign up via our website.

Thanks for your patience.

https://t.co/QRtHqpC08J | https://t.co/H61cCD0w9R

#Autism #ASD #AutismTreatment #AutismResearch #l179

[yamopharma @yamopharma]

Autism families do not measure hope in slogans. They measure it in a longer conversation, a calmer moment, and a connection that was not there before.

L1-79 is the only drug in the world under development to treat the core symptoms of autism, moving into Phase 3 testing.

Phase 2 showed a meaningful gain on the Vineland 3 Socialization Standard Score versus placebo. Phase 3 is planned for 2027.

For answers to your frequently asked questions visit: https://t.co/4rm7TtvNSS

To get involved, click on the contact page of https://t.co/QRtHqpC08J

Thank you for being a part of this journey.

#Autism #AutismParents #AutismResearch #L179 #YamoPharma

[yamopharma @yamopharma]

This is the kind of social change families with autism describe when they talk about L1-79.

Not a cure.

A possible opening toward connection.

L1-79 is an experimental treatment now moving toward Phase 3 trials.

Learn more at https://t.co/ErnMMLHPGt

[yamopharma @yamopharma]

For autism families, the hardest gap is often social communication: starting a conversation, staying in it, and building a relationship that lasts.

L1-79 is an investigational therapy being developed for those core symptoms. The program is designed around pathways that influence attention, behavior, and social connection.

Phase 2 showed a clinically meaningful gain on the Vineland 3 Socialization Standard Score versus placebo. Phase 3 is planned for 2027.

Read our free FAQ on trial timing, eligibility, and what investigational means at https://t.co/4rm7TtvNSS

#Autism #AutismResearch #L179 #ASD #ClinicalTrials

[yamopharma @yamopharma]

Parents of children with autism in the early L1-79 trials kept coming back to moments like this.

Small social breakthroughs that changed the feel of daily life.

L1-79 is an experimental treatment focused on the social aspects of autism and is preparing for Phase 3 trials in 2027.

Learn more at https://t.co/QRtHqpC08J

#autism #autismtreatment #autismawareness #ASD #l179

[yamopharma @yamopharma]

With autism, a meaningful gain is often a conversation that lasts, a look that holds, or a connection that was not there last month.

That is the outcome families hope for.

L1-79 is an investigational oral therapy designed for those core social communication symptoms.

Phase 2 showed a clinically meaningful gain on the Vineland 3 Socialization Standard Score versus placebo. Phase 3 is planned for 2027.

We just published a free FAQ that answers the questions families send most. Read it at https://t.co/4rm7TtvNSS

#Autism #AutismParents #AutismResearch #L179 #ASD

[yamopharma @yamopharma]

Phase 3 FDA testing is the step that can turn a promising autism signal into a real answer for social communication. It is also the step that cannot start on hope alone.

L1-79 is an investigational oral therapy designed for core social communication symptoms. Phase 2 showed a clinically meaningful gain on the Vineland 3 Socialization Standard Score versus placebo. Phase 3 is next.

Learn more at https://t.co/QRtHqpC08J

#Autism #AutismResearch #L179 #YamoPharma #ClinicalTrials

[yamopharma @yamopharma]

Autism families from all over the world have similar questions about L1-79.

When does Phase 3 start? Can younger kids join? Can anyone order L1-79?

Today we answered the questions that showed up most, without slogans and without false hope.

Subscribe to our FREE weekly newsletter.

New every Friday.

https://t.co/4rm7TtvNSS

#Autism #AutismParents #AutismResearch #L179 #YamoPharma

@elonmusk @RobertKennedyJr @haleymossart

[yamopharma @yamopharma]

@ProfoundAutism Connecting trials to the profound-autism community is important. That’s where core social-communication challenges are often most disabling and least well served by current options.

[yamopharma @yamopharma]

@speechpathology This is a useful framing for drug development: target the common pathway effects, then measure whether core social-communication function actually changes.

[yamopharma @yamopharma]

@psycheureka Worth looking at how this trial defined social improvement. Core social measures are where the evidence base is thinnest.

[yamopharma @yamopharma]

@PaulWhiteleyPhD Communication and quality-of-life endpoints should sit at the center of more trials. Families keep asking for research that changes day-to-day function.

[yamopharma @yamopharma]

So many families living with autism share the same quiet wish for their children to connect more easily with the world around them.

L1-79 is an experimental treatment aimed at those social challenges and is moving toward Phase 3.

Thank you for trusting us with your stories.

Learn more at https://t.co/QRtHqpC08J

#autism #autismacceptance #asd #science #l179

[yamopharma @yamopharma]

It’s the small things that count.

Autism families often measure progress in a glance held a second longer, a question asked out of nowhere, or sudden interest in someone else’s day. Those are the moments that rewrite a household.

L1-79 is an investigational oral therapy designed for the core social communication symptoms of autism. It targets a catecholamine pathway involved in attention, behavior, and connection. Phase 2 showed a clinically meaningful gain on the Vineland 3 Socialization Standard Score versus placebo. Phase 3 is next.

Follow the latest at https://t.co/eZIWvZOG3d

#Autism #AutismParents #AutismResearch #L179 #YamoPharma

[yamopharma @yamopharma]

Parents of children with autism keep writing to us about the gap between having words and being able to truly connect.

We hear you.

L1-79 is an experimental treatment focused on the social aspects of autism and is preparing for Phase 3 trials.

Learn more at https://t.co/QRtHqpC08J

#autism #autismtreatment #asd #science #l179

@elonmusk @RobertKennedyJr @NationalAutism

[yamopharma @yamopharma]

Sensory challenges are a major part of the autism experience for many.

Dr. Tom Megerian highlights how sensory integration tools and neurodiversity affirming therapies that respect unique wiring while building skills can combine powerfully with emerging medical research.

What sensory strategies or tools have helped in your world? Drop them in the comments 👇

Join the full conversation on our Substack at https://t.co/H61cCCZYkj

#autism #autismtreatment #asd #science #l179

[yamopharma @yamopharma]

L1-79 is the only drug in the world under development to treat the core symptoms of autism, moving into phase 3. It targets a catecholamine pathway involved in attention, behavior, and social connection.

In Phase 2, it showed a clinically meaningful gain on the Vineland-3 Socialization Standard Score versus placebo.

Phase 3 is scheduled to start in 2027.

Data and updates: https://t.co/QRtHqpBsjb

#Autism #AutismResearch #L179 #YamoPharma

[yamopharma @yamopharma]

Parents of children with autism are writing to us every day with this exact hope.

L1-79 is an experimental treatment designed to address the social symptoms of autism.

Phase 3 trials for L1-79 are scheduled for 2027.

Thank you for sharing your stories with us.

Learn more at https://t.co/QRtHqpBsjb

#autism #autismtreatment #ASD #L179 #hope